Clinical Trial News and Research

RSS

MicroRNA can be used as a biomarker to predict breast cancer recurrence and mortality, study says

MicroRNA (miRNA) can be used as a biomarker to predict which patients are likely to face breast cancer recurrence and mortality, according to study results published online ahead of print in the Journal of the American College of Surgeons.

6 Nov 2022

Two heart failure therapies prove to be nearly identical in reducing death

In a head-to-head comparison of two so-called 'water pills' that keep fluid from building up in patients with heart failure, the therapies proved nearly identical in reducing deaths, according to a large study led by Duke Health researchers.

6 Nov 2022

Moderna's COVID-19 vaccine safe and effective in children 6 months to 5 years of age

Moderna's COVID-19 vaccine is safe and effective in children 6 months to 5 years of age, a clinical trial co-led by Vanderbilt University Medical Center vaccine expert C. Buddy Creech, MD, MPH, has found.

4 Nov 2022

Charles River Laboratories: New Center Expands Cell and Gene Therapy Capabilities

In this interview, Niall Dinwoodie, Executive Director for Gene Therapy for Charles River in Europe discusses the opening of their new HQ Plasmid Center of Excellence at Alderley Park.

From Charles Rivers Laboratories Cell and Gene Therapy 4 Nov 2022

H pylori eradication protects against aspirin-associated peptic ulcer bleeding

A new study, led by experts at the University of Nottingham found that the risk of stomach bleeding caused by using aspirin long-term, can be reduced with a short course of antibiotics, potentially improving the safety of aspirin when used to prevent heart attacks, strokes and possibly some cancers.

4 Nov 2022

Weekly weight loss drug reduces BMI in teens

Researchers report that a weekly dose of semaglutide led to a significant BMI reduction in adolescents.

3 Nov 2022

New evaluation data shows the clinical utility of SOPHiA DDM Dx HRD Solution

SOPHiA GENETICS, a cloud-native software company in the healthcare space, debuted new data at the European Society of Gynaecological Oncology (ESGO) Congress as part of a poster (#PA-065) presented by Prof. Alexandre Harlé of the Institut de Cancérologie de Lorraine, France.

3 Nov 2022

Targeted therapy for children with high-risk Hodgkin lymphoma reduces relapse rates, trial shows

A targeted therapy for children with high-risk Hodgkin lymphoma (HL) was shown to significantly reduce relapse rates when tested in a large multicenter clinical trial conducted by the Children's Oncology Group (COG) and led by pediatric oncologists at Roswell Park Comprehensive Cancer Center, Children's Healthcare of Atlanta and Winship Cancer Institute of Emory University. By combining the targeted antibody-drug conjugate (ADC) brentuximab vedotin (BV) with the standard chemotherapy regimen, children were 10% less likely to relapse.

2 Nov 2022

Many middle-aged adults unlikely to participate in dementia prevention clinical trials

Right now, drug companies and university-based teams are working urgently to find and test new medications that could prevent or slow the decline of brain function in older adults.

2 Nov 2022

First-of-its-kind computer model simulates a clinical trial evaluating two Alzheimer’s drugs

An estimated 6.2 million Americans ages 65 and older are living with Alzheimer's disease. The national Alzheimer's Association predicts that number to grow to 13.8 million by 2060, barring the development of medical breakthroughs that would prevent, slow or cure the debilitating disease.

2 Nov 2022

Researchers identify new therapeutic approach against treatment-resistant prostate cancer

Investigators from Cedars-Sinai Cancer have identified an investigational therapeutic approach that could be effective against treatment-resistant prostate cancer. Results of their Phase II clinical trial, published in the peer-reviewed journal Molecular Therapy, have led to a larger, multicenter trial that will soon be underway.

2 Nov 2022

Study identifies a root cause of chronic heart failure following a heart attack

A multi-institution study led by Rohan Dharmakumar, PhD, of Indiana University School of Medicine, has identified that iron drives the formation of fatty tissue in the heart and leads to chronic heart failure in about fifty percent of heart attack survivors.

1 Nov 2022

Researchers offer new insights into the neurobiological basis of autism spectrum disorders

Findings from a new study published in Cell Reports, involving a collaborative effort between researchers at the Luikart Laboratory at Dartmouth's Geisel School of Medicine and the Weston Laboratory at the University of Vermont, are providing further insight into the neurobiological basis of autism spectrum disorders (ASD) and pointing to possible treatments.

1 Nov 2022

The maternal RSV vaccine from Pfizer protects newborns against severe illness

Pfizer announced its maternal vaccine against RSV to be almost 82% effective in protecting infants for the first 90 days of life against severe illness.

1 Nov 2022

Cohort study determines how often COVID-19 symptoms recurred

Researchers at University of California San Diego School of Medicine, with colleagues from the ACTIV-2 trial, part of the U.S. government's response to COVID-19, investigated whether symptoms of COVID-19 recurred following a two-day symptom-free period in persons who did not receive any treatment for the disease.

1 Nov 2022

Monoclonal antibody shows efficacy in preventing malaria infection in African adults

One dose of an antibody drug safely protected healthy, non-pregnant adults from malaria infection during an intense six-month malaria season in Mali, Africa, a National Institutes of Health clinical trial has found.

31 Oct 2022

New device could help address racial disparities in hemoglobin and blood oxygen measurements

A team led by a University of Texas at Arlington bioengineering professor and an Austin businessman has published key findings in the British Medical Journal Innovations that illustrate how a new device measures hemoglobin more accurately in individuals with darker skin pigmentations.

28 Oct 2022

First anti-SARS Cov2 monoclonal antibody candidate of SpikImm demonstrates excellent tolerance

SPK001, the first anti-SARS Cov2 monoclonal antibody candidate of SpikImm, a French biotechnology company founded by Truffle Capital, originally discovered by the Institut Pasteur's Human Immunology Laboratory, directed by Dr. Hugo Mouquet (Inserm Joint Research Unit), has been tested on three initial cohorts of healthy volunteers, and has demonstrated excellent tolerance, in the context of the Phase 1 clinical study, recently labeled as a "national priority" by CAPNET (National Steering Committee for Therapeutic Trials and other Research on Covid-19).

28 Oct 2022

Research reveals a differential clinical response to pembrolizumab in uterine cancer patients

New research from Yale Cancer Center reveals for the first time ever a differential clinical response to pembrolizumab in Lynch-like (mutated) vs methylated microsatellite instability-high (MSI-H) uterine cancer patients, increasing our understanding about the proportion of patients that derive benefit from immune checkpoint blockade.

28 Oct 2022

Study sheds light on why some patients respond better than others to immunotherapy

Immunotherapy, a biotherapy that boosts the ability of the immune system to recognize and attack mutant tumor cells, has transformed the treatment landscape for patients battling cancer, which emerges from the progressive accumulation of DNA mutations.

27 Oct 2022

Clinical Trial News and Research

MicroRNA can be used as a biomarker to predict breast cancer recurrence and mortality, study says

Two heart failure therapies prove to be nearly identical in reducing death

Moderna's COVID-19 vaccine safe and effective in children 6 months to 5 years of age

Charles River Laboratories: New Center Expands Cell and Gene Therapy Capabilities

H pylori eradication protects against aspirin-associated peptic ulcer bleeding

Weekly weight loss drug reduces BMI in teens

New evaluation data shows the clinical utility of SOPHiA DDM Dx HRD Solution

Targeted therapy for children with high-risk Hodgkin lymphoma reduces relapse rates, trial shows

Many middle-aged adults unlikely to participate in dementia prevention clinical trials

First-of-its-kind computer model simulates a clinical trial evaluating two Alzheimer’s drugs

Researchers identify new therapeutic approach against treatment-resistant prostate cancer

Study identifies a root cause of chronic heart failure following a heart attack

Researchers offer new insights into the neurobiological basis of autism spectrum disorders

The maternal RSV vaccine from Pfizer protects newborns against severe illness

Cohort study determines how often COVID-19 symptoms recurred

Monoclonal antibody shows efficacy in preventing malaria infection in African adults

New device could help address racial disparities in hemoglobin and blood oxygen measurements

First anti-SARS Cov2 monoclonal antibody candidate of SpikImm demonstrates excellent tolerance

Research reveals a differential clinical response to pembrolizumab in uterine cancer patients

Study sheds light on why some patients respond better than others to immunotherapy

Event guide: 15th World Clinical Biomarkers & CDx Europe eBook

Latest eBooks

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Driving innovation in Korean drug development

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Applications Engineer